Oligomerization partially explains the lowering of Aβ42 in Alzheimer's disease cerebrospinal fluid
2009 (English)In: Neuro-degenerative diseases, ISSN 1660-2862, Vol. 6, no 4, 139-147 p.Article in journal (Refereed) Published
Background/aim: The lowering of natively analyzed Aβ42 in cerebrospinal fluid (CSF) is used as a diagnostic tool in Alzheimer’s disease (AD). Presence of Aβ oligomers can interfere with such analyses causing underestimation of Aβ levels due to epitope masking. The aim was to investigate if the lowering of CSF Aβ42 seen is caused by oligomerization. Methods: Aβ42 was analyzed under both denaturing and non-denaturing conditions. An Aβ42 oligomer ratio was calculated from these quantifications. Presence of oligomers leads to Aβ42 epitope masking during non-denaturing assays, resulting in a higher ratio. Results: The Aβ42 oligomer ratio was used for assessment of oligomerized Aβ in human CSF, after being evaluated in transgenic mouse brain homogenates. AD and mild cognitive impairment (MCI) samples displayed the expected decrease in natively measured Aβ42 compared to healthy controls and frontotemporal dementia, but not when analyzing under denaturing conditions. Accordingly, AD and MCI CSF had a higher Aβ42 oligomer ratio in CSF. Conclusion: Combining denaturing and non-denaturing quantifications of Aβ42 into an oligomer ratio enables assessment of Aβ oligomers in biological samples. The increased Aβ42 oligomer ratio for AD and MCI indicates presence of oligomers in CSF and that the lowering of natively measured Aβ42 is caused by oligomerization.
Place, publisher, year, edition, pages
2009. Vol. 6, no 4, 139-147 p.
Alzheimer’s disease, CSF, Amyloid-β, oligomers
Medical and Health Sciences
Research subject Geriatrics
IdentifiersURN: urn:nbn:se:uu:diva-98510DOI: 10.1159/000225376ISI: 000269623400001PubMedID: 19521063OAI: oai:DiVA.org:uu-98510DiVA: diva2:174743